Second-line treatment options in hepatocellular carcinoma
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the...
Sábháilte in:
Príomhchruthaitheoirí: | , , , , |
---|---|
Formáid: | LEABHAR |
Foilsithe / Cruthaithe: |
BioExcel Publishing Ltd,
2019-04-01T00:00:00Z.
|
Ábhair: | |
Rochtain ar líne: | Connect to this object online. |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
Gairmuimhir: |
A1234.567 |
---|---|
Cóip 1 | Ar fáil |